SCHEMBL6316599

SCHEMBL6316599

Cc1[nH]c2ccc([N+](=O)[O-])cc2c1C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSV O60911 2/20 0.53
CTSL P07711 2/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 1/20 0.52
LMNA P02545 2/20 0.52
PDE1C Q14123 1/20 0.52
POLB P06746 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
PKM P14618 1/20 0.50
NPY1R P25929 1/20 0.50
NPY2R P49146 1/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.47
ALOX5 P09917 1/20 0.47
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315808 0.83 GAA (0.74) NPC1RAB9AKMT2AGAALMNA
SCHEMBL6315952 0.81 GAA (0.56) NPC1RAB9AKMT2AGAALMNA
SCHEMBL6318356 0.81 GAA (0.55) NPC1RAB9AKMT2AGAALMNA
SCHEMBL28524078 0.80 MEN1 (0.58) CTSVCTSLNPC1RAB9AKMT2A
SCHEMBL6317032 0.80 GAA (0.54) NPC1RAB9AKMT2AGAALMNA
SCHEMBL5327852 0.79 ALDH1A1 (0.68) CTSVCTSLKMT2AGAALMNA
SCHEMBL6317295 0.79 GAA (0.53) NPC1RAB9AKMT2AGAALMNA
SCHEMBL7827626 0.79 GAA (0.53) NPC1RAB9AKMT2AGAALMNA
SCHEMBL6635342 0.78 KMT2A (0.52) CTSVCTSLKMT2AGAALMNA
Hydrochloric Acid SCHEMBL6317289 0.78 GAA (0.52) NPC1RAB9AKMT2AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 CTSV 1340/4885CTSL 860/4885NPC1 1589/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 CTSV 1008/4885CTSL 596/4885NPC1 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.